BrainStorm Receives Notice of Allowance on US Patent


Follow this company

Companies Mentioned

OTC:BB:BCLI
07/28/2014 [ACCESSWIRE]

NEW YORK, NY and PETACH TIKVAH, Israel / ACCESSWIRE / July 28, 2014 / BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, received Notice of Allowance from the United States Patent Office for Patent Application 12/994,761, titled "Mesenchymal Stem Cells for the Treatment of CNS Diseases."

This patent covers the use of mesenchymal stem cells that secrete elevated levels of brain-derived neurotrophic factor (BDNF) to treat diseases of the central nervous system, including but not limited to Amyotrophic Lateral Sclerosis (ALS), Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, multiple sclerosis, among others.  The Patent Office recognized a priority date for this patent of May 28, 2008.

"We are gratified that the US Patent Office has recognized the innovative nature of NurOwn, our proprietary, differentiated mesenchymal stem cells, for use in treating a variety of neurologic diseases," commented BrainStorm’s CEO Tony Fiorino, MD, PhD., "This important patent represents yet another step forward in our intellectual property strategy, and we continue to aggressively pursue patents on all of our commercially important discoveries."

This patent falls under the company’s licensing agreement with Ramot, the technology transfer organization of Tel Aviv University, and reflects the continued collaboration between the company and the laboratory of Prof. Dani Offen, the company's chief scientist.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company’s website at www.brainstorm-cell.com.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential",  and similar terms and phrases are intended to identify these forward-looking statements.  The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.  These factors should be considered carefully, and readers should not place undue reliance on BrainStorm’s forward-looking statements.  The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Contact

BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI)

Mr. Tony Fiorino, CEO

Phone: +972-3-9236384

info@brainstorm-cell.com

US Investor Contact

LifeSci Advisors, LLC

Michael Rice

Phone: 646-597-6979

mrice@lifesciadvisors.com

 

 

SOURCE: BrainStorm Cell Therapeutics Inc.

COMMENTS

Leave a comment...
 * 

Your Name
 *